**Market Opportunity:**
Multidrug-resistant *A. baumannii* is a rapidly emerging pathogen in the healthcare setting, where it causes infections that include bacteremia, pneumonia, meningitis, urinary tract infection and wound infection. The organism's ability to survive under a wide range of environmental conditions and to persist on surfaces for extended periods make it a frequent cause of outbreaks of infection. The development of new therapies to target this pathogen would have a substantial impact on controlling its transmission and provide treatment where there are currently limited therapeutic agents available.

**USC Solution:**
USC researchers have generated monoclonal antibodies that specifically target *A. baumannii*. This has resulted in three new monoclonal antibodies. The intent is to develop a cocktail of monoclonal antibodies that bind to almost all strains as a therapeutic to treat deadly *A. baumannii* infections.

**Applications**
- Monoclonal antibodies as a therapeutic to specifically target *A. baumannii*

**Stage of Development**
- Development and characterization of the mouse hybridomas; characterization of binding efficiencies
- Available for exclusive license

** Intellectual Property**
**Status:**
Provisional patent to be filed

**Key Publication:**
“New Societal Approaches to Empowering Antibiotic Stewardship” *JAMA*, 315:12 1229-1230 (2016)

**Value Proposition**
- Limited current therapeutics targeting *A. baumannii*
- Monoclonal antibodies specifically target *A. baumannii*
- Novel composition of matter
- Novel method for raising the monoclonal antibodies against *A. baumannii*
- Highly efficient binding capacity of antibody to its target

**Keywords:**
*A. baumannii*, monoclonal antibodies, infectious disease and therapeutics, antimicrobial resistance, superbug

**Contact information**
**David Mellman**
Licensing Associate, Life Sciences
(213) 821-3545
dmellman@usc.edu

Maximizing the translation of USC research into products for public benefit